Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Aug. 26, 2021—BD has launched its FDA-approved BD COR PX/GX system, a fully automated, high-throughput diagnostic platform that integrates robotics and sample management software algorithms to automate the complete molecular laboratory workflow from sample processing to diagnostic test result.
Aug. 25, 2021—Siemens Healthineers announced that its Enhanced Liver Fibrosis test was granted marketing authorization under the de novo review pathway.
Aug. 24, 2021—Hardy Diagnostics has released its HardyChrom Group A Strep agar, a chromogenic medium recommended for the selective cultivation and differentiation of group A streptococcus from clinical specimens.
Aug. 16, 2021—Siemens Healthineers has launched Sysmex’s CN-3000 and CN-6000 hemostasis systems for mid- and high-volume coagulation testing.
Aug. 13, 2021—Bio-Rad Laboratories has launched SARS-CoV-2 S gene alpha, beta, gamma, and epsilon variant controls.
Aug. 12, 2021—Siemens Healthineers has developed the Atellica COVID-19 Severity Algorithm, a model designed to help predict the potential likelihood of progression to severe disease and life-threatening multiorgan dysfunction in COVID-19 patients.
Aug. 6, 2021—Qiagen received emergency use authorization from the FDA for its QIAreach SARS CoV-2 Antigen Test.
Aug. 4, 2021—Immunovia has received approval to begin patient testing for the IMMray PanCan-d blood test for the early detection of pancreatic cancer.
July 29, 2021—Promega’s OncoMate MSI Dx analysis system has been cleared by the FDA as an IVD medical device to determine microsatellite instability status in colorectal cancer tumors.
July 20, 2021—Sarstedt introduced its BL 1200 Sort Connect, a preanalytical accessioning and sorting instrument that can be connected to integrated systems or analyzer lines.
